Liraglutide
FDAEvidence
Tier 1 · FDA-approved · Phase 3 RCTs
metabolicweight-lossdiabetes
CYCLE: ongoing · DOSE: 0.6–3.0 mg/day SC
12mo research activity
17 studies indexed
View peptide →Peptides tracked
20
Studies indexed
394
Experiences logged
2
Last updated
Apr 2026
The peptide reference built by the people using them.
Trending peptides
All 20 peptides
BPC-157
Evidence
Tier 3 · 27 studies (preclinical)
healingrecoverytissue-repair
CYCLE: — · DOSE: see notes
27 studies indexed
View peptide →CJC-1295
Evidence
Tier 3 · 20 studies (preclinical)
gh-releasemusclerecovery
CYCLE: — · DOSE: —
20 studies indexed
View peptide →DSIP
Evidence
Tier 2 · 27 studies · RCT evidence
sleeprecovery
CYCLE: — · DOSE: see notes
27 studies indexed
View peptide →Epitalon
Evidence
Tier 3 · 29 studies (preclinical)
longevitysleepanti-aging
CYCLE: — · DOSE: —
29 studies indexed
View peptide →GHK-Cu
Evidence
Tier 3 · 12 studies (preclinical)
skinanti-aginghair
CYCLE: — · DOSE: —
12 studies indexed
View peptide →Hexarelin
Evidence
Tier 3 · 16 studies (preclinical)
gh-releasecardioprotectionrecovery
CYCLE: — · DOSE: —
16 studies indexed
View peptide →Ipamorelin
Evidence
Tier 2 · 14 studies · RCT evidence
growth-hormonegh-release
CYCLE: — · DOSE: see notes
14 studies indexed
View peptide →Kisspeptin
Evidence
Tier 3 · 13 studies (preclinical)
reproductivehormonal
CYCLE: — · DOSE: —
13 studies indexed
View peptide →KPV
Evidence
Tier 3 · 15 studies (preclinical)
gut-healthinflammation
CYCLE: — · DOSE: —
15 studies indexed
View peptide →Liraglutide
FDAEvidence
Tier 1 · FDA-approved · Phase 3 RCTs
metabolicweight-lossdiabetes
CYCLE: ongoing · DOSE: 0.6–3.0 mg/day SC
17 studies indexed
View peptide →MK-677
Evidence
Tier 2 · 14 studies · RCT evidence
gh-releasemuscleappetite
CYCLE: 8w-2y · DOSE: 25mg/day PO
14 studies indexed
View peptide →MOTS-c
Evidence
Tier 3 · 29 studies (preclinical)
metabolicmitochondrialongevity
CYCLE: — · DOSE: —
29 studies indexed
View peptide →Selank
Evidence
Tier 3 · 19 studies (preclinical)
anxietynootropicfocus
CYCLE: — · DOSE: —
19 studies indexed
View peptide →Semaglutide
FDAEvidence
Tier 1 · FDA-approved · Phase 3 RCTs
metabolicweight-lossfat-loss
CYCLE: — · DOSE: 0.5-1mg/wk SC
27 studies indexed
View peptide →Semax
Evidence
Tier 3 · 11 studies (preclinical)
nootropicneuroprotectionfocus
CYCLE: — · DOSE: —
11 studies indexed
View peptide →Sermorelin
Evidence
Tier 3 · 12 studies (preclinical)
gh-releaseanti-agingsleep
CYCLE: — · DOSE: see notes
12 studies indexed
View peptide →TB-500
Evidence
Tier 3 · 16 studies (preclinical)
healingrecoveryinflammation
CYCLE: — · DOSE: —
16 studies indexed
View peptide →Tesamorelin
FDAEvidence
Tier 1 · FDA-approved · Phase 3 RCTs
growth-hormonemetabolicfat-loss
CYCLE: ongoing · DOSE: 2mg/day SC
19 studies indexed
View peptide →Thymosin Alpha-1
Evidence
Tier 3 · 29 studies (observational)
immuneinflammation
CYCLE: — · DOSE: —
29 studies indexed
View peptide →Tirzepatide
FDAEvidence
Tier 1 · FDA-approved · Phase 3 RCTs
metabolicweight-lossfat-loss
CYCLE: ongoing · DOSE: 5-15mg/wk SC
28 studies indexed
View peptide →Latest research
BPC-157 Accelerates Tendon-to-Bone Repair in Murine Models
Researchers demonstrate significant upregulation of healing markers at the enthesis, with evidence suggesting a systemic rather than purely local mechanism of action.
J. Orthopaedic Research →GLP-1 Receptor Agonists: Expanding Evidence for Cardiovascular Protection
Meta-analysis of 14 trials finds semaglutide and tirzepatide reduce major adverse cardiac events independent of weight loss magnitude.
New England J. Medicine →TB-500 Peptide Fragment: Angiogenesis and Skeletal Muscle Repair Mechanisms
Study characterises the pro-angiogenic pathway activated by Thymosin Beta-4 fragments in injured skeletal muscle tissue.
Peptides →Growth Hormone Secretagogues and IGF-1: Updated 2025 Safety Profile Review
Comprehensive review of ipamorelin and GHRP class compounds finds favourable short-term safety data; calls for longer-term trials.
Endocrinology & Metabolism →Tesamorelin Reduces Visceral Adiposity Independent of Dietary Intervention
Randomised controlled trial shows significant visceral fat reduction in adults over 24 weeks without caloric restriction.
J. Clinical Endocrinology →Have experience with a peptide? Your protocol may help others researching the same compound.
Anonymous submissions. No account required.